Medical research technology provider Medidata agreed last month to acquire US-based life sciences analytics platform Shyft Analytics for $195m, having invested in the company in 2016.
Shyft has developed a cloud-based platform that enables pharmaceutical and biotech researchers to drive relevant information from large amounts of complex data.
Medidata owned a 6% stake in Shyft pre-acquisition, after taking part in the first tranche of a series B round that closed at $20m in March 2017 with participation from pharmaceuticals distributor McKesson and Optum Ventures, a subsidiary of care provider UnitedHealth.
Private equity firm Health Enterprise Partners (HEP) and venture capital fund Milestone Venture Partners also invested in the series B round. Shyft had received $15m in series A funding from HEP in 2013, before Milestone added $4m to the round the following year.